Early Development Choices Define Scalability And Product Quality In CGT

In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene stress that early-stage process decisions have lasting downstream effects on product quality, scalability, and speed to clinic. Luman highlights the need to define key parameters such as cell isolation, media composition, and gene editing methods early, while ensuring processes are adaptable to automation and closed systems. Luke cautions that adopting inflexible, all-in-one platforms too soon can limit innovation later, and he underscores the importance of comprehensive early data capture to guide future process evolution.